Evidence map›Paper›PMID 35417485›Full record

ArticlePloS one2022

Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.

Jennifer Velloza, Nicole Poovan, Nontokozo Ndlovu, Nomhle Khoza, Jennifer F Morton, Jeanne Omony, Edwin Mkwanazi, Cole Grabow, Deborah Donnell, Richard Munthali and 4 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04038060 (Evaluation of Stepped PrEP), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04038060 nacompletednot on this map

Evaluation of Stepped PrEP (Pre-exposure Prophylaxis) Adherence Support for Young South African Women Using a SMART Design

TypeinterventionalSponsorUniversity of WashingtonRan2019 to 2022Enrolled360ConditionsHIV/AIDSArmsWhatsApp Group, 2-way SMS, Drug level feedback, Monthly counseling sessions
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jennifer VellozaDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0001-7242-7415
Nicole PoovanWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Nontokozo NdlovuWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Nomhle KhozaWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Jennifer F MortonDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Jeanne OmonyWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Edwin MkwanaziWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Cole GrabowDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0003-2006-8654
Deborah DonnellDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Richard MunthaliWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.
Jared M BaetenDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Sybil HosekDepartment of Psychiatry, Stroger Hospital of Cook County, Chicago, IL, United States of America.
Connie CelumDepartment of Global Health, University of Washington, Seattle, WA, United States of America.
Sinead Delany-MoretlweWits Reproductive Health & HIV Institute (Wits RHI), Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-0376-1019

Funding

PrEP for Young South African Women: Evaluating Uptake by Risk Screening or a Decision Support Tool and Scaled Adherence Support Using a SMART DesignR01MH114544 · NIMH · UNIVERSITY OF WASHINGTON · PI CELUM, CONNIE L, DELANY-MORETLWE, SINEAD · 2017 to 2021
$3.1M
Adaptation and optimization of the Friendship Bench mental health intervention for adolescent girls and young women in South African PrEP delivery settingsK99MH123369 · NIMH · UNIVERSITY OF WASHINGTON · PI VELLOZA, JENNIFER · 2021 to 2022
$181k
NIMH NIH HHS K99 MH123369NIMH NIH HHS R01 MH114544
6 · The paper itself

Abstract

introductionPre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy and is recommended for populations at risk of HIV, including adolescent girls and young women (AGYW) in HIV endemic settings. However, PrEP continuation and high adherence remain challenges to its impact. Existing PrEP adherence interventions can be time- and cost-intensive. Widescale PrEP delivery will require the identification of layered PrEP support strategies for AGYW with diverse prevention needs. We describe the design of a sequential multiple assignment randomized trial (SMART) to evaluate a PrEP adherence support model using scalable, stepped interventions in AGYW in South Africa.

methods"PrEP SMART" is a randomized trial in Johannesburg, South Africa, enrolling AGYW who are between 18 and 25 years of age, sexually active, newly initiating PrEP, and have regular access to a mobile phone. Participants are randomized 1:1 to standard-of-care PrEP counseling with either two-way SMS or WhatsApp group adherence support. Adherence is assessed at three months using tenofovir diphosphate (TFV-DP) levels from dried blood spots collected at month 2 to categorize participants as "responders" (TFV-DP ≥500 fmol/punch) or "non-responders" (TFV-DP <500 fmol/punch). AGYW defined as 'non-responders' undergo a secondary 1:1 randomization to either quarterly drug-level feedback counseling or monthly issue-focused counseling, in addition to their first-level intervention. The primary outcome is PrEP adherence at nine months (TFV-DP ≥700 fmol/punch). We will assess the effect of our two initial interventions on TFV-DP levels among responders, assess the effect of our intensified interventions on TFV-DP levels among non-responders, and identify the optimal sequence of adherence interventions through nine months.

trial registrationClinicalTrials.gov, NCT04038060. Registered on 30 July 2019.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentFemaleHumansMedication AdherenceRandomized Controlled Trials as TopicSouth AfricaAnti-HIV Agents

Identifiers

PMID35417485
PMCPMC9007385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.